Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme

Neuro-Oncology

Volumn 12, Issue 9, 2010, Pages 908-916

  Khayal, Inas S ^a,b   Polley, Mei Yin C ^a   Jalbert, Llewellyn ^b   Elkhaled, Adam ^b   Chang, Susan M ^a   Cha, Soonmee ^a,b   Butowski, Nicholas A ^a   Nelson, Sarah J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apparent diffusion coefficient; Diffusionweighted imaging; Disease progression; Fractional anisotropy; Glioblastoma multiforme

Indexed keywords

ANGIOGENESIS INHIBITOR; PROTEIN KINASE C BETA INHIBITOR; TEMOZOLOMIDE;

ADULT; AGED; ANISOTROPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DIFFUSION TENSOR IMAGING; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GLIOBLASTOMA; HUMANS; PROGNOSIS; RADIOTHERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 77958000207     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq049     Document Type: Article

References (32)

1. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neurooncology. 2002;4:278-299.
2. Legler JM, Ries LA, Smith MA, et al. Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst. 1999;91:1382-1390.
3. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
4. van den Bent MJ, Vogelbaum MA,Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol. 2009;27: 2905-2908.
5. Wong ET, Brem S. Taming glioblastoma: targeting angiogenesis. J Clin Oncol. 2007;25:4705-4706.
6. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol. 2007;25:4104-4109. (Pubitemid 47495868)
7. Mardor Y, Roth Y, Lidar Z, et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res. 2001;61:4971-4973.
8. Mardor Y, Pfeffer R, Spiegelmann R, et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol. 2003;21:1094-1100.
9. Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA. 2005;102:16759-16764.
10. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92:2029-2036.
11. Tomura N, Narita K, Izumi J, et al. Diffusion changes in a tumor and peritumoral tissue after stereotactic irradiation for brain tumors: possible prediction of treatment response. J Comput Assist Tomogr. 2006;30: 496-500.
12. Schubert MI, Wilke M, Muller-Weihrich S, Auer DP. Diffusion-weighted magnetic resonance imaging of treatment-associated changes in recurrent and residual medulloblastoma: preliminary observations in three children. Acta Radiol. 2006;47:1100-1104.
13. Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg. 2004;100:472-479.
14. Chenevert TL, McKeever PE, Ross BD. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res. 1997;3:1457-1466.
15. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neurooncology. 2008;10:162-170.
16. Polley MC, Lamborn KR, Chang S, et al. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly-diagnosed glioblastoma patients receiving temozolomide. Neurooncology. 2009.
17. Teicher BA, Menon K, Alvarez E, et al. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts. Clin Cancer Res. 2001;7:634-640. (Pubitemid 32707989)
18. Aeder SE, Martin PM, Soh JW, Hussaini IM. PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways. Oncogene. 2004;23:9062-9069.
19. Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B. 1996;111:209-219.
20. Hartkens T, Rueckert D, Schnabel JA, Hawkes DJ, Hill DLG. VTK CISG Registration Toolkit: An Open Source Software Package for Affine and Non-Rigid Registration of Single- and Multimodal 3D Images. BVM2002, Leipzig: Springer-Verlag; 2002.
21. Nelson SJ, Nalbandian AB, Proctor E, Vigneron DB. Registration of images from sequential MR studies of the brain. J Magn Reson Imaging. 1994;4:877-883.
22. Saraswathy S, Crawford F, Nelson S. Semi-automated segmentation of brain tumor lesions in MR images (abstract 1609). Proceedings of the 14th Annual Meeting of ISMRM, Seattle, WA, USA, 2006.
23. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectationmaximization algorithm. IEEE Trans Med Imaging. 2001;20:45-57.
24. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA. 2005;102:5524-5529.
25. Hamstra DA, Galban CJ, Meyer CR, et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008;26:3387-3394.
26. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20:1375-1382.
27. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252:182-189.
28. Sinha S, Bastin ME, Whittle IR. Rapid clinical deterioration in a patient with multi-focal glioma despite corticosteroid therapy: a quantitative MRI study. Br J Neurosurg. 2003;17:537-540; discussion 540.
29. Sinha S, Bastin ME, Wardlaw JM, Armitage PA, Whittle IR. Effects of dexamethasone on peritumoural oedematous brain: a DT-MRI study. J Neurol Neurosurg Psychiatry. 2004;75:1632-1635.
30. Bastin ME, Carpenter TK, Armitage PA, et al. Effects of dexamethasone on cerebral perfusion and water diffusion in patients with high-grade glioma. AJNR Am J Neuroradiol. 2006;27:402-408.
31. Armitage PA, Schwindack C, Bastin ME, Whittle IR. Quantitative assessment of intracranial tumor response to dexamethasone using diffusion, perfusion and permeability magnetic resonance imaging. Magn Reson Imaging. 2007;25:303-310.
32. Minamikawa S, Kono K, Nakayama K, et al. Glucocorticoid treatment of brain tumor patients: changes of apparent diffusion coefficient values measured by MR diffusion imaging. Neuroradiology. 2004;46:805-811.